1. IQVIA. The impact of biosimilar competition in Europe. 2020. Available from: https://www.iqvia.com/library/white-papers/the-impact-of-biosimilar-competition-in-europe. [Accessed 16 Jan 2021].
2. IQVIA. The global use of medicines 2022: outlook to 2026. 2021. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/the-global-use-of-medicines-2022/global-use-of-medicines-2022-outlook-to-2026-12-21-forweb.pdf. [Accessed 16 Dec 2021].
3. IQVIA. The impact of biosimilar competition in Europe. 2021. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/emea/the-impact-of-biosimilar-competition-in-europe-iqvia.pdf. [Accessed 3 Jan 2022].
4. Dutta B, Huys I, Vulto AG, Simoens S. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34:159–70.
5. European Medicines Agency. Biosimilars in the EU: information guide for healthcare professionals. 2017. Available from: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. [Accessed 28 Jul 2022].